BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
Immix Biopharma (IMMX) was in focus on Tuesday as BofA grew more confident in the prospects for its lead CAR-T therapy, NXC-201, following encouraging new clinical data in a rare disease characterized by harmful protein buildup in organs.BofA raised its price target on Immix to $30 from $27 while m…